Cargando…
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing (13)C(6)-glucose metabolic flux analysis, we show for the first time that...
Autores principales: | Fack, Fred, Espedal, Heidi, Keunen, Olivier, Golebiewska, Anna, Obad, Nina, Harter, Patrick N., Mittelbronn, Michel, Bähr, Oliver, Weyerbrock, Astrid, Stuhr, Linda, Miletic, Hrvoje, Sakariassen, Per Ø., Stieber, Daniel, Rygh, Cecilie B., Lund-Johansen, Morten, Zheng, Liang, Gottlieb, Eyal, Niclou, Simone P., Bjerkvig, Rolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282692/ https://www.ncbi.nlm.nih.gov/pubmed/25322816 http://dx.doi.org/10.1007/s00401-014-1352-5 |
Ejemplares similares
-
Lack of functional normalisation of tumour vessels following
anti-angiogenic therapy in glioblastoma
por: Obad, Nina, et al.
Publicado: (2017) -
Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
por: Huszthy, Peter C., et al.
Publicado: (2015) -
Correction: Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
por: Huszthy, Peter C., et al.
Publicado: (2015) -
In vivo models of primary brain tumors: pitfalls and perspectives
por: Huszthy, Peter C., et al.
Publicado: (2012) -
Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma
por: Bougnaud, Sébastien, et al.
Publicado: (2016)